RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND THERAPEUTICS COMMITTEE

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met in Salem, Oregon on Thursday, January 25, 2017. The Committee considered in order of priority: the safety and efficacy of the drugs being considered, the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions and finally, substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staff and all public comment offered, while considering the impact on special populations, the Committee makes the following recommendations for the Oregon Practitioner-Managed Prescription Drug Plan (PMPDP) or for any other preferred drug list established by the Oregon Health Authority:

Drug Use Review Recommendations:

Drugs for Asthma and COPD Literature Scan

The Committee approved removing the coverage of uncomplicated chronic bronchitis from the ICS, LABA, LABA/ICS and LAMA/LABA PA criterion as this is no longer a funded diagnosis. The Committee also recommended adopting the proposed changes to the LAMA/LABA PA criteria to accommodate Trelegy Ellipta. After comparative cost consideration in executive session, the Committee recommended making no changes to the PMPDP.

Hepatitis C Direct-Acting Antivirals Policy

The Committee recommended modifying the proposed language in the DAA PA criteria to clarify and simply list type 2 diabetes and remove proposed insulin resistance definition. The Committee also requested staff bring back the substance use disorder question with evidence to September P&T meeting.
Practitioner-Managed Prescription Drug Plan (PMPDP) Recommendations:

Biologics for Autoimmune Conditions Class Update

The Committee recommended updating the PA Criteria to: change the table heading to approved and funded conditions; add new and updated indications to the approved indications table; add guselkumab and sarilumab to the criteria and to remove natalizumab from biologic PA criteria. After review in executive session the Committee recommended no other changes to the PMPDP, but to modify the PA criteria to require trial and failure of preferred Humira or Enbrel products.

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors Class Review

The Committee recommended creating a new class for VMAT2 inhibitors on the PMPDP and to implement the proposed PA criteria – after amending to remove the question concerning specific diagnoses - for valbenazine, deutetabenazine and tetrabenazine to ensure appropriate use. Due to limited efficacy and safety data, the Committee recommended designating all products non-preferred.

After review in executive session the Committee recommended no changes to the PMPDP and to refer the VMAT2 Inhibitor class to the Health Evidence Review Commission (HERC) for prioritization consideration and to update the PA criteria if needed.

PCSK-9 Inhibitors Class Update

The Committee recommended continuing to require prior authorization for approval of evolocumab and alirocumab and to approve for high CV risk patients that have been included in clinical studies and to modify the required trial length of a high-intensity statin and ezetimibe to 3 months in question #4 and to remove the time restriction for a recent LDL-C. The Committee also approved modifying the definition for clinical atherosclerotic cardiovascular disease in question #3 to include peripheral vascular disease and require at least one additional major risk factor or 2 minor risk factors to mirror inclusion criteria of the FOURIER clinical trial. After comparative cost consideration in executive session, the Committee recommended making no changes to the PMPDP.

The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority.
APPROVAL BY THE DIRECTOR OF THE OREGON HEALTH AUTHORITY

The recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee are approved. Recommendations with respect to the inclusion of a drug on the Practitioner-Managed Prescription Drug Plan will be put into place no earlier than 60 days from the date this notice is posted on the web site.

The recommendation to refer the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor class to the Health Evidence Review Commission (HERC) will be taken under further advisement. The Director accepts the other PA criteria and PMPDP elements described in the VMAT2 class review.

3/6/18

Patrick Allen          Approval date
Director

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 30 calendar days from the date of this notice. 2011 OR law, CH 730 (HB2100) Section 4

2http://pharmacy.oregonstate.edu/drug-policy/oregon-pharmacy-therapeutics-committee/meetings-agenda